JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/hMmrifhiNN https://t.co/LPHc5GyOaA
Links:
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodg…
https://buff.ly/3VHX7pj
Jun-26-2024
